Santhera Pharmaceuticals Holding AG SANN

SWX: SANN | ISIN: CH0027148649 5/05/2025

14,52 CHF (-1,09%)

(-1,09%) 5/05/2025

Grafiek Santhera Pharmaceuticals Holding AG

Grafiek Santhera Pharmaceuticals Holding AG

1 dag1d -1,09%
1 week1w 0,00%
1 maand1m 9,50%
3 maanden3m -11,89%
6 maanden6m 73,89%
1 jaar1j 58,34%
5 jaar5j 83,80%

Santhera Pharmaceuticals Holding AG in het nieuws

Toon enkel gratis nieuws

29 april 2025 · Santhera Publishes Agenda for its Annual General Meeting · Persbericht

29 april 2025 · Santhera Full Year Results for the Year Ended 31 December 2024 · Persbericht

16 april 2025 · Santhera shares updates on commercial rollout of AGAMREE® · Persbericht

27 maart 2025 · Santhera proposes Dr. Melanie Rolli as new member of Board of Directors · Persbericht

24 maart 2025 · Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day · Persbericht

4 maart 2025 · Full Year Trading Update · Persbericht

13 februari 2025 · Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany · Persbericht

10 februari 2025 · Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted · Persbericht

16 januari 2025 · Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy · Persbericht

16 januari 2025 · Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia · Persbericht

Profiel Santhera Pharmaceuticals Holding AG

CEO: Dario Eklund

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe